Cargando…
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients
BACKGROUND: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472407/ https://www.ncbi.nlm.nih.gov/pubmed/26055271 http://dx.doi.org/10.1186/s13045-015-0163-z |
_version_ | 1782377052233531392 |
---|---|
author | Loghavi, Sanam Alayed, Khaled Aladily, Tariq N. Zuo, Zhuang Ng, Siok-Bian Tang, Guilin Hu, Shimin Yin, C. Cameron Miranda, Roberto N. Medeiros, L. Jeffrey Khoury, Joseph D. |
author_facet | Loghavi, Sanam Alayed, Khaled Aladily, Tariq N. Zuo, Zhuang Ng, Siok-Bian Tang, Guilin Hu, Shimin Yin, C. Cameron Miranda, Roberto N. Medeiros, L. Jeffrey Khoury, Joseph D. |
author_sort | Loghavi, Sanam |
collection | PubMed |
description | BACKGROUND: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. PATIENTS AND METHODS: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. RESULTS: Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p = 0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p = 0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p = 0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p = 0.047) but not OS (p = 0.306). Notably, OS was adversely impacted by age ≥50 years (p = 0.013), stage III or IV disease (p = <0.001), and lymph node involvement (p = 0.008). CONCLUSIONS: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0163-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4472407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44724072015-06-20 Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients Loghavi, Sanam Alayed, Khaled Aladily, Tariq N. Zuo, Zhuang Ng, Siok-Bian Tang, Guilin Hu, Shimin Yin, C. Cameron Miranda, Roberto N. Medeiros, L. Jeffrey Khoury, Joseph D. J Hematol Oncol Research Article BACKGROUND: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. PATIENTS AND METHODS: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. RESULTS: Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p = 0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p = 0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p = 0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p = 0.047) but not OS (p = 0.306). Notably, OS was adversely impacted by age ≥50 years (p = 0.013), stage III or IV disease (p = <0.001), and lymph node involvement (p = 0.008). CONCLUSIONS: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-015-0163-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-10 /pmc/articles/PMC4472407/ /pubmed/26055271 http://dx.doi.org/10.1186/s13045-015-0163-z Text en © Loghavi et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Loghavi, Sanam Alayed, Khaled Aladily, Tariq N. Zuo, Zhuang Ng, Siok-Bian Tang, Guilin Hu, Shimin Yin, C. Cameron Miranda, Roberto N. Medeiros, L. Jeffrey Khoury, Joseph D. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
title | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
title_full | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
title_fullStr | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
title_full_unstemmed | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
title_short | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
title_sort | stage, age, and ebv status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472407/ https://www.ncbi.nlm.nih.gov/pubmed/26055271 http://dx.doi.org/10.1186/s13045-015-0163-z |
work_keys_str_mv | AT loghavisanam stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT alayedkhaled stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT aladilytariqn stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT zuozhuang stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT ngsiokbian stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT tangguilin stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT hushimin stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT yinccameron stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT mirandaroberton stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT medeirosljeffrey stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients AT khouryjosephd stageageandebvstatusimpactoutcomesofplasmablasticlymphomapatientsaclinicopathologicanalysisof61patients |